2026 Q1
SunRay101 antibody screening expected to be completed in Q1 2026.
Metabolic Disease Therapeutics:
Metabolic Disease Therapeutics:
Precision Medicines Reshaping Metabolic Homeostasis
Precision Medicines Reshaping Metabolic Homeostasis
- Over 650 million people worldwide are living with obesity, yet no single drug can simultaneously achieve fat loss, muscle preservation, and correction of multiple metabolic disorders.
- Approximately 40% of weight loss from current anti-obesity drugs comes from muscle mass, leading to reduced metabolism and high rebound risk;no approved therapy currently exists for sarcopenia.
SUNRAY Approach
Leveraging the SoIndeep™ and SolnAb™ platforms, we are developing innovative biologics targeting both the ActRII and GIPR pathways. The ActRII subtype-selective monoclonal antibody (SunRay101) blocks muscle wasting signaling while preserving metabolic homeostasis-related pathways; the ActRII/GIPR bispecific antibody (SunRay102) achieves synergistic fat reduction and muscle gain while improving glucolipid metabolism.
Indications
Obesity, Sarcopenia, Type 2 Diabetes, Heart Failure with Muscle Wasting, and beyond.
Clinical Value
Offers patients with metabolic syndrome a single therapeutic solution addressing multiple pathologies, with particular strength in filling the current gap in muscle preservation.
Technology Infrastructure
R&D across all four application domains is supported by the following three technology platforms:
Metabolic Disease Therapeutics
Musculoskeletal Regeneration
Regenerative Biomaterials
Smart Health Management
AI De Novo Antibody Platform
Directly generates antibodies against antigen epitopes, reducing R&D costs by 70%
AI Cell Screening Platform
Tens of millions of data points accumulated; participates in industry standard-setting
AI Biomaterial Composite Design Platform
Multi-physics simulation reduces experimental workload by over 50%
Key Milestones
-
-
2026
China's first tendon stem cell IIT clinical trial was approved at the Second Affiliated Hospital of Zhejiang University.
-
2026 Q2
PLLA microspheres have completed enrollment of 240+ patients (Class III medical device).
-
2026
Longevity Clinic to be established in 2026.
